AstraZeneca Can't Block Generic Crestor: Fed. Circ.
In affirming the dismissal of nine suits, a three-judge panel rejected AstraZeneca's contention that its claims were warranted because generic versions of Crestor would be prescribed for any possible condition even if regulators approved them for unpatented uses.
“[I]f accepted, these speculative arguments would allow...
To view the full article, register now.